AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
49 hedge funds and large institutions have $33.2M invested in AVEO Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 5 closing their positions.
200% more call options, than puts
Call options by funds: $9K | Put options by funds: $3K
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
107% more capital invested
Capital invested by funds: $16M → $33.2M (+$17.2M)
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
11% more funds holding
Funds holding: 44 → 49 (+5)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$4.33M |
| 2 |
AC
Armistice Capital
New York
|
+$3.47M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$2.84M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.09M |
| 5 |
6CM
683 Capital Management
New York
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$496K |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$280K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$158K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$127K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$51K |
AVEO Hedge Fund Activity: Q1 2017 in Review
49 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2017, worth a combined $33.2M — up 107% from $16M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AVEO positions and 5 closed out — a net gain of 9 holders — while 12 added to existing stakes and 6 trimmed.
The largest buyer was NEA Management Company, adding an estimated $4.33M. The largest seller was Sarissa Capital Management, cutting an estimated $496K.
- 49 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2017, up from 44 in Q4 2016.
- Funds reported $33.2M of AVEO Pharmaceuticals, Inc. stock for Q1 2017, up 107% quarter-over-quarter.
- 14 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2017 and 5 closed out, a net change of +9 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q1 2017 was NEA Management Company, an estimated $4.33M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q1 2017 was Sarissa Capital Management, an estimated $496K sold.
Based on aggregated 13F filings for Q1 2017.